| Cassandra Ma Perkins, CADC,CRMII,PSS | |
|
58646 Mcnulty Way, Saint Helens, OR 97051-6210 | |
| (503) 397-5211 | |
| (503) 397-5373 |
| Full Name | Cassandra Ma Perkins |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 58646 Mcnulty Way, Saint Helens, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063746469 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cassandra Ma Perkins, CADC,CRMII,PSS Po Box 1234, Saint Helens, OR 97051-8234 Ph: (503) 397-5211 | Cassandra Ma Perkins, CADC,CRMII,PSS 58646 Mcnulty Way, Saint Helens, OR 97051-6210 Ph: (503) 397-5211 |
News Archive
New treatments for dry eye disease that deliver lipids to the ocular surface are designed to more closely mimic the important tear film lipid layer at the air-water interface in the eye.
The U.S. Food and Drug Administration announced today that certain tobacco products introduced or changed after Feb. 15, 2007 must be reviewed by the agency. In FDA guidance published today, the agency outlines a pathway for marketing a product whereby the company marketing the product must prove that it is "substantially equivalent" to products commercially available on Feb. 15, 2007.
Fake medicines increasingly put patients and the general public at risk across the world. In response to this challenge, ten partners who represent healthcare professionals, disease-specific organizations, product-development partnerships, foundations, international financing institutions, as well as the research-based pharmaceutical industry have joined forces to raise awareness about the dangers of fake medicines.
Whitehead Institute researchers have determined a key part of how cells regulate the chromosome/microtubule interface, which is central to proper chromosomal distribution during cell division.
Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.
› Verified 4 days ago
Sandra Anne Petersen-tetz, CADC I Counselor Medicare: Not Enrolled in Medicare Practice Location: 185 N 4th St, Saint Helens, OR 97051 Phone: 503-366-4540 Fax: 503-366-4526 | |
Ruth Deleon, M.A, Counselor Medicare: Not Enrolled in Medicare Practice Location: 58646 Mcnulty Way, Saint Helens, OR 97051 Phone: 503-397-5211 | |
Megan J Parks, Counselor Medicare: Not Enrolled in Medicare Practice Location: 58646 Mcnulty Way, Saint Helens, OR 97051 Phone: 503-397-5211 | |
Heather Lorene Swanson, B.S. Counselor Medicare: Not Enrolled in Medicare Practice Location: 58646 Mcnulty Way, Saint Helens, OR 97051 Phone: 503-397-5211 | |
Ben Louis Weaver, LPC, NCC, QMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 58646 Mcnulty Way, Saint Helens, OR 97051 Phone: 503-397-5211 Fax: 503-438-2194 | |
Sierra Marie Dibble, Counselor Medicare: Not Enrolled in Medicare Practice Location: 58147 Columbia River Hwy Ste C, Saint Helens, OR 97051 Phone: 503-396-5322 | |
Tabatha L Bird Weaver, LPC,MA, MFT Counselor Medicare: Not Enrolled in Medicare Practice Location: 58646 Mcnulty Way, Saint Helens, OR 97051 Phone: 503-397-5211 Fax: 503-397-5373 |